Avid Bioservices Inc (CDMO)

[sulaco]

NO EXPERIMENT IS EVER A FAILURE


We thought we were toast with SUNRISE termination, but that failed trial may hold the key to PPHM's success.

The consensus continues to build on a multi-angled attack on the tumor microenvironment. Repolarize M2 macrophages back to M1 with Bavi, radiate locally, and then add in your anti-XYZers. Bang. The tumor crumbles AND adaptive memory keeps it from coming back. (Remember, that as of today, a tremendous number of breast cancer "survivors" go on to get cancer in the OTHER breast.)

Avid record profits, cancer diagnosis kits pending, and Bavi synergizing beautifully as the Board has always known it; the pieces are coming together.

Now add in our failed SUNRISE. The protein biomarker data will identify those patients most like to respond. With cancer at epidemic levels, don't worry, brothers. Bavi will find its place in so many solid cancers.

Wolchok knows this!


Best,

Joe Six-Pack

p.s. sorry I went missing for a few months there. I'm back, buying more than ever, and as optimistic as EVER. Cheers.